GlassScriptPhysician profile
Natalie M Smith
NPI 1831489590
$3,006.99
in general payments reported to CMS, 2019-2025
26 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $198 · 2021: $566 · 2022: $293 · 2023: $192 · 2024: $168 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $446.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $353.24 | 2019-2025 | |
| Amarin Pharma, INC. | $307.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $267.49 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $227.56 | 2019-2025 | Ubrelvy |
| Amgen INC. | $198.14 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $186.29 | 2019-2021 | |
| Exact Sciences Corporation | $180.38 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $170.72 | 2019-2022 | |
| Astellas Pharma US INC | $170.26 | 2019-2022 | |
| Lilly USA, LLC | $99.79 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.99 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $50.22 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $39.09 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $31.11 | 2023 | Impella |
| Allergan, INC. | $25.17 | 2020 | |
| Adlon Therapeutics L.P. | $22.09 | 2019 | |
| Dynavax Technologies Corporation | $20.61 | 2024 | Heplisav-B |
| Insmed, INC. | $17.42 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.81 | 2021 | |
| Dexcom, INC. | $15.90 | 2021 | |
| Genentech USA, INC. | $14.44 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.35 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.